WSE-listed leader in AI-powered cardiac diagnostic software continues its strong growth trajectory, recording a 30% year-over-year revenue increase in August. With the planned launch of additional functionalities within the DRP platform at the turn of September and October, the Management Board believes there is significant potential to further increase total revenues from U.S. client contracts, including one of the largest IDTFs in terms of diagnostic sessions.
“The August results confirm that we have entered the period of accelerated growth we previously announced, following the completion of the first stage of our business transformation. Faster onboarding of new clients generating recurring revenues has delivered the intended results. However, it is important to note that we are only at the beginning of this process – we have integrated just 4 out of 15 new clients so far. This leaves substantial potential for additional revenue growth, with future dynamics largely dependent on the pace of integration. Moreover, with the upcoming launch of new functionalities for clients at the turn of September and October, coupled with strong prospects for signing new contracts, we are confident that the company has the potential to achieve revenues exceeding prior expectations, although the pace of realization will depend on successful client integration” commented Dr. Kris Siemionow, CEO of Medicalgorithmics. “In parallel with intensive integration efforts, we are already engaged in advanced discussions with additional prospective partners. This further reinforces our conviction that our growth strategy, built around innovative cardiac diagnostic software, has the potential to deliver increasingly strong results in the coming quarters” added Dr. Siemionow.
Medicalgorithmics represents a successful transformation towards scalable AI-driven services, with an increasing share of software-derived revenues and a strong position in the global telemedicine market. Since the beginning of this year, the WSE-listed medtech company has been expanding dynamically, onboarding and activating new clients. The company signed a record 15 agreements (more than in the whole of 2024), which contributed to a significant increase in its share price. Since the start of the year, Medicalgorithmics has doubled its market capitalization, becoming one of the best-performing investments on the Warsaw Stock Exchange in 2025.
Among the newly signed contracts, in addition to the previously mentioned U.S. clients, are: an agreement with a European IDTF, a partnership with a U.S. deep-tech company specializing in the integration of advanced materials, sensors, and artificial intelligence, as well as the first two commercial contracts for VCAST – on the Turkish market and the strategically important Scandinavian market.
The integration and testing phase with a client’s infrastructure – which can only commence after a contract is signed – typically takes 6–10 months. As a result, Medicalgorithmics expects to begin monetizing several of its newly signed agreements later this year.